—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Novocure Ltd (NVCR) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for NVCR, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 1.28 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How NVCR has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 1.28 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Novocure Ltd moved 1.28% on average · correlation 0.15 · higher than 94% of US names
  • Beta, last 3 months 1.52 more rate-sensitive lately than over the year
  • On the 10 worst bond days −3.34% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −0.31% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Medical Devices · United States · 8 names with week and year-to-date

Peer group

Medical Devices · United States

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against NVCR on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Novocure Ltd

NVCR in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Novocure develops, manufactures and sells tumour treating fields devices, wearable systems that deliver low-intensity electric fields to disrupt the division of cancer cells in solid tumours. Its marketed products, Optune Gio, Optune Lua and Optune Pax, address specific cancers and are sold in the United States, Germany, France, Japan, Greater China and other markets. The company also runs trials testing the same technology in brain metastases, gastric, glioblastoma, liver, lung, pancreatic and ovarian cancers. It is headquartered in Baar, Switzerland.
Where it sits in the stack
Novocure carries no seat in Rubin, our AI build-out index, so it sits outside that stack entirely. Within our wider universe it belongs to the Healthcare sector, medical devices sleeve, alongside other therapeutic-device makers rather than any layer of the compute build-out.
Who it is priced against
Closelooknet has not set a peer group for Novocure. The market sometimes places it alongside other therapeutic medical-device makers such as Medtronic, though the comparison is loose given how specific its tumour treating fields technology is.
Why Closelooknet tracks it
Novocure is a Russell 1000 constituent; Closelooknet has not built a score for it, and the diary has not yet quoted the name in any edition.
What the diary watches
The diary watches whether trial results in cancers beyond its current approvals, such as lung, liver or pancreatic cancer, would widen the addressable use of its devices.

Novocure Ltd (NVCR) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Novocure Ltd (NVCR)?

Novocure Ltd trades as NVCR on the US exchange (United States) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is NVCR in a Closelooknet index?

Not currently — Novocure Ltd is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does NVCR trade against its moving averages?

Pullback inside an uptrend stack: Trades -5.4% vs the 50-day and +8.1% vs the 200-day average, 26.2% below the 52-week high and +61.3% off the 52-week low. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Novocure Ltd trade when bond yields rise?

Over the past year Novocure Ltd had a beta of 1.28 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 94% of US names. On the 10 sessions in which long bonds fell most it moved −3.34% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Novocure Ltd do?

Novocure develops, manufactures and sells tumour treating fields devices, wearable systems that deliver low-intensity electric fields to disrupt the division of cancer cells in solid tumours. Its marketed products, Optune Gio, Optune Lua and Optune Pax, address specific cancers and are sold in the United States, Germany, France, Japan, Greater China and other markets. The company also runs trials testing the same technology in brain metastases, gastric, glioblastoma, liver, lung, pancreatic and ovarian cancers. Closelooknet has not set a peer group for Novocure. The market sometimes places it alongside other therapeutic medical-device makers such as Medtronic, though the comparison is loose given how specific its tumour treating fields technology is.

Where does Novocure Ltd sit in the AI build-out?

Novocure carries no seat in Rubin, our AI build-out index, so it sits outside that stack entirely. Within our wider universe it belongs to the Healthcare sector, medical devices sleeve, alongside other therapeutic-device makers rather than any layer of the compute build-out. Novocure is a Russell 1000 constituent; Closelooknet has not built a score for it, and the diary has not yet quoted the name in any edition.

What does this page show?

A live price chart with SMA overlays and drawing tools for NVCR, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Medical Devices. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.